Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADCIRCA vs ATMEKSI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phosphodiesterase-5 (PDE5) inhibitor; increases c GMP in pulmonary vascular smooth muscle, leading to vasodilation.
ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.
Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise capacity and delay clinical worsening.,Off-label: Erectile dysfunction (not FDA-approved for this indication in the context of PAH).
Treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg,Off-label use as part of antiretroviral therapy in treatment-experienced patients with viral suppression
10 mg orally three times daily.
1.5 mg/kg IV every 4 weeks
Terminal half-life: 10–15 hours in healthy adults; prolonged in hepatic impairment (Child-Pugh B/C: up to 30 hours); clinical context: supports twice-daily dosing
Terminal elimination half-life is 12 hours; renally impaired patients have prolonged half-life up to 24 hours.
Primarily metabolized by CYP3A4 (major) and CYP2C9 (minor) hepatic enzymes.
Atazanavir is metabolized by CYP3A4; cobicistat is metabolized by CYP3A and to a minor extent by CYP2D6.
Renal: ~70% (metabolites and unchanged drug), Fecal: ~20%, Biliary: minor
Primarily renal (80% unchanged) and biliary/fecal (15% as metabolites).
96% bound to albumin and alpha-1-acid glycoprotein
95% bound to albumin and alpha-1-acid glycoprotein.
Vd: 0.4–0.7 L/kg; suggests distribution into total body water and moderate tissue binding
2.0 L/kg, indicating extensive tissue distribution.
Oral: 80%; absolute bioavailability: 50% due to first-pass metabolism
Oral: 60-70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment; avoid use in severe impairment (Cr Cl <30 m L/min) due to lack of data.
GFR 15-29 m L/min: 1.0 mg/kg IV every 4 weeks; GFR <15 m L/min: not recommended
Mild to moderate hepatic impairment (Child-Pugh A or B): 10 mg orally once daily; severe hepatic impairment (Child-Pugh C): contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: 1.0 mg/kg IV every 4 weeks; Child-Pugh C: not recommended
Not established for patients <18 years.
Age 2-17 years: 1.5 mg/kg IV every 4 weeks; maximum 120 mg per dose
No specific dose adjustment, but caution due to increased sensitivity; monitor renal function.
No specific adjustment; monitor renal function and reduce dose if GFR <30 m L/min
Do not use in patients taking nitrates (regularly or intermittently) due to risk of severe hypotension.
None
Risk of hypotension, especially with nitrates or alpha-blockers.,Hematologic effects: increased risk of bleeding due to antiplatelet activity; caution with bleeding disorders or anticoagulants.,Vision loss: non-arteritic anterior ischemic optic neuropathy (NAION) has been reported; discontinue if sudden vision loss occurs.,Hearing loss: sudden decrease or loss of hearing; may be accompanied by tinnitus or dizziness.,Use caution in patients with left ventricular outflow obstruction (e.g., aortic stenosis) or severely impaired autonomic control of blood pressure.,Dose adjustment required with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir).
Hepatotoxicity, especially in patients with pre-existing liver disease or elevated transaminases,Nephrolithiasis and cholelithiasis,Cardiac conduction abnormalities (PR interval prolongation),Risk of developing resistance if not used with other antiretrovirals,Renal impairment (cobicistat decreases estimated creatinine clearance)
Concomitant use of nitrates (any form) or nitric oxide donors.,Concomitant use with riociguat or other guanylate cyclase stimulators.,Known hypersensitivity to tadalafil or any component of the product.,Severe hepatic impairment (Child-Pugh class C).
Concomitant use with drugs highly dependent on CYP3A for clearance (e.g., alfuzosin, rifampin, ergot derivatives, St. John's wort, lovastatin, simvastatin, sildenafil for pulmonary arterial hypertension),Severe hepatic impairment (Child-Pugh Class B or C)
Avoid grapefruit and grapefruit juice as they may increase tadalafil levels and risk of side effects. No other significant food interactions. High-fat meals may delay absorption but do not require dose adjustment.
Avoid alcohol (may exacerbate CNS effects). Grapefruit juice may increase atomoxetine exposure; limit consumption. High-fat meals do not significantly affect absorption.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but there are no adequate and well-controlled studies in pregnant women. First trimester: risk cannot be ruled out; use only if clearly needed. Second and third trimesters: no known fetal risks, but caution advised due to maternal hypotension risk.
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: No known fetal risks. Avoid use during organogenesis unless benefit outweighs risk.
Not recommended. Excretion in human milk unknown. M/P ratio not established. Risk of hypotension in neonate. Alternative feeding method advised during therapy and for 48 hours after last dose.
Not recommended during breastfeeding. M/P ratio unknown. Excreted in animal milk; potential for serious adverse reactions in nursing infants.
No specific pharmacokinetic data in pregnancy. Standard dose (40 mg orally once daily) recommended. Monitor for hypotension; dose adjustment not routinely required unless maternal hypotension develops.
No dose adjustment required in pregnancy. Pharmacokinetic profile unchanged.
Adcirca (tadalafil) is a PDE5 inhibitor indicated for pulmonary arterial hypertension (PAH) to improve exercise ability. It is dosed at 40 mg once daily, not as needed. Avoid use with nitrates due to risk of severe hypotension. Monitor for vision loss (non-arteritic anterior ischemic optic neuropathy) and hearing loss. Use caution in patients with hepatic impairment (Child-Pugh class B: reduce dose; class C: contraindicated). Dose adjustment required with potent CYP3A4 inhibitors (e.g., ketoconazole: reduce to 20 mg). Not recommended for severe renal impairment (Cr Cl <30 m L/min) or on hemodialysis.
ATMEKSI (atomoxetine) is a selective norepinephrine reuptake inhibitor (NRI) indicated for ADHD. It has a slower onset of action (2-4 weeks) compared to stimulants. Monitor for hepatotoxicity and suicidal ideation, especially in children and adolescents. Use cautiously with hepatic impairment (reduce dose) and CYP2D6 poor metabolizers (need lower dose). Avoid concurrent MAOIs. May cause orthostatic hypotension and urinary retention.
Take Adcirca exactly as prescribed, 40 mg once daily, at the same time each day. Do not take it as needed for erectile dysfunction.,Do not take Adcirca if you are taking any form of nitrate medication (e.g., nitroglycerin) or recreational drugs called 'poppers' (amyl nitrate) as this can cause a sudden dangerous drop in blood pressure.,Seek immediate medical attention if you experience sudden vision loss or decrease in hearing, as these may be signs of a serious side effect.,Avoid drinking large amounts of alcohol (e.g., 3 or more drinks) within a short time while taking Adcirca, as it may increase the risk of dizziness, lightheadedness, and fainting.,Inform your healthcare provider about all medications you take, including prescription, over-the-counter, and herbal products, especially alpha-blockers, erythromycin, or ritonavir.,Adcirca may cause dizziness. Do not drive or operate machinery until you know how the medicine affects you.
Take ATMEKSI exactly as prescribed; do not change dose without consulting your doctor.,It may take 2-4 weeks to notice improvement in symptoms.,Avoid alcohol and grapefruit juice as they may affect drug levels.,Report any signs of liver problems (yellowing of skin/eyes, dark urine, abdominal pain) or suicidal thoughts immediately.,May cause dizziness or fainting, especially when standing up; rise slowly.,Do not stop abruptly without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADCIRCA vs ATMEKSI, answered by our medical review team.
ADCIRCA is a PDE5 Inhibitor that works by Phosphodiesterase-5 (PDE5) inhibitor; increases c GMP in pulmonary vascular smooth muscle, leading to vasodilation.. ATMEKSI is a PDE5 Inhibitor that works by ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADCIRCA and ATMEKSI depend on the specific clinical indication. These are both PDE5 Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADCIRCA is: 10 mg orally three times daily.. The standard adult dose of ATMEKSI is: 1.5 mg/kg IV every 4 weeks. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADCIRCA and ATMEKSI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADCIRCA is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but there are no adequate and well-controlled studies in pregnant women. First trimester: risk cannot be rule. ATMEKSI is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: No known fetal risks. Avoid use during organogenesis u. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.